[144] Emergent BioSolutions Inc. SEC Filing
Rhea-AI Filing Summary
Emergent BioSolutions (EBS) received a Form 144 notice for a proposed sale of 17,801 common shares, showing an aggregate market value of $187,544.22. The filing lists Morgan Stanley Smith Barney LLC Executive Financial Services as broker and identifies the NYSE as the exchange, with an approximate sale date of 11/10/2025.
The shares were acquired as restricted stock from the issuer on 10/02/2025, in the same amount of 17,801 shares. The notice also reports a prior sale in the last three months by Donald DeGolyer of 7,844 common shares on 08/12/2025 for $67,830.99. Shares outstanding are listed as 52,519,964.
Positive
- None.
Negative
- None.
Insights
Routine Form 144 for 17,801 EBS shares; neutral signal.
This notice records an affiliate’s intent to sell up to 17,801 common shares under Rule 144, with an aggregate market value of $187,544.22. The broker is Morgan Stanley Smith Barney LLC Executive Financial Services, and the filing cites an approximate sale date of 11/10/2025 on the NYSE.
The shares were acquired as restricted stock on 10/02/2025. The filing also notes a prior sale in the past three months by Donald DeGolyer of 7,844 shares for $67,830.99. Shares outstanding are listed as 52,519,964. These details are administrative and do not, by themselves, alter the investment thesis.